CPT Pharmacometrics & Systems Pharmacology · 2019 · 46 citations · 39 references
PharmacyPharmacokineticsPharmacologyPharmacodynamicsPharmacokinetic ModelingPharmacokinetic-pharmacodynamic ModelingAntibody CharacterizationAntibody PharmacokineticsImmunoglobulin FunctionPharmacokinetics Of Monoclonal AntibodiesTherapeutic Antibody DevelopmentFcrn-mediated RecyclingNeonatal Fc Receptor BindingNeonatal Fc Receptor RecyclingPh-dependent BehaviorPh-dependent Binding KineticsPh-responsive BindingPk Model BuildingTransgenic Mouse Models
Monoclonal antibody (mAb) pharmacokinetics (PK) have largely been predicted via allometric scaling with little consideration for cross-species differences in neonatal Fc receptor (FcRn) affinity or clearance/distribution mechanisms. To address this, we developed a mAb physiologically-based PK model that describes the intracellular trafficking and FcRn recycling of mAbs in a human FcRn transgenic homozygous mouse and human. This model uses mAb-specific in vitro data together with species-specific FcRn tissue expression, tissue volume, and blood-flow physiology to predict mAb in vivo linear PK a priori. The model accurately predicts the terminal half-life of 90% of the mAbs investigated within a twofold error. The mechanistic nature of this model allows us to not only predict linear PK from in vitro data but also explore the PK and target binding of mAbs engineered to have pH-dependent binding to its target or FcRn and could aid in the selection of mAbs with optimal PK and pharmacodynamic properties.
39
An estimation of the number of cells in the human body
Eva Bianconi, Allison Piovesan, Federica Facchin et al. · Annals of Human Biology · 2013 · 1K citations · Full text
Life Sciences, Biology, Cell Biology +11